Home LiteratureArticle Details
PMID: 16079851 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Nature ·Vol. 436 ·No. 7051 ·2005-08-04 ·Pages 725-30

Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP

Abstract

Cellular senescence has been theorized to oppose neoplastic transformation triggered by activation of oncogenic pathways in vitro, but the relevance of senescence in vivo has not been established. The PTEN and p53 tumour suppressors are among the most commonly inactivated or mutated genes in human cancer including prostate cancer. Although they are functionally distinct, reciprocal cooperation has been proposed, as PTEN is thought to regulate p53 stability, and p53 to enhance PTEN transcription. Here we show that conditional inactivation of Trp53 in the mouse prostate fails to produce a tumour phenotype, whereas complete Pten inactivation in the prostate triggers non-lethal invasive prostate cancer after long latency. Strikingly, combined inactivation of Pten and Trp53 elicits invasive prostate cancer as early as 2 weeks after puberty and is invariably lethal by 7 months of age. Importantly, acute Pten inactivation induces growth arrest through the p53-dependent cellular senescence pathway both in vitro and in vivo, which can be fully rescued by combined loss of Trp53. Furthermore, we detected evidence of cellular senescence in specimens from early-stage human prostate cancer. Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours.

MeSH Terms
ADP-Ribosylation Factors/metabolism Animals Cell Transformation, Neoplastic/genetics,metabolism,pathology Cells, Cultured Cellular Senescence Female Fibroblasts Male Mice PTEN Phosphohydrolase Phenotype Phosphoric Monoester Hydrolases/deficiency,genetics,metabolism Prostatic Neoplasms/genetics,metabolism,pathology Survival Analysis Tumor Suppressor Protein p53/deficiency,genetics,metabolism Tumor Suppressor Proteins/deficiency,genetics,metabolism
Chemicals
Tumor Suppressor Protein p53 Tumor Suppressor Proteins Phosphoric Monoester Hydrolases PTEN Phosphohydrolase ADP-Ribosylation Factors
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Chen Zhenbang
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA.
Trotman Lloyd C
Shaffer David
Lin Hui-Kuan
Dotan Zohar A
Niki Masaru
Koutcher Jason A
Scher Howard I
Ludwig Thomas
Gerald William
Cordon-Cardo Carlos
Pandolfi Pier Paolo
References (30)
30 references, click to expand
  1. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
    Genes Chromosomes Cancer. 2004 Mar;39(3):171-84 PMID: 14732919
  2. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
    Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603 PMID: 11504915
  3. Cancer mortality surveillance--United States, 1990-2000.
    MMWR Surveill Summ. 2004 Jun 4;53(3):1-108 PMID: 15179359
  4. Leveling of prostate cancer mortality in Western Europe.
    Prostate. 2004 Jun 15;60(1):46-52 PMID: 15129428
  5. Cellular senescence as a tumor-suppressor mechanism.
    Trends Cell Biol. 2001 Nov;11(11):S27-31 PMID: 11684439
  6. A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
    Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 PMID: 7568133
  7. Pten dose dictates cancer progression in the prostate.
    PLoS Biol. 2003 Dec;1(3):E59 PMID: 14691534
  8. Regulation of PTEN transcription by p53.
    Mol Cell. 2001 Aug;8(2):317-25 PMID: 11545734
  9. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.
    Cancer Cell. 2003 Feb;3(2):117-30 PMID: 12620407
  10. Molecular genetics of prostate cancer.
    Genes Dev. 2000 Oct 1;14(19):2410-34 PMID: 11018010
  11. Putting the stress on senescence.
    Curr Opin Cell Biol. 2001 Dec;13(6):748-53 PMID: 11698192
  12. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Nat Med. 2002 Mar;8(3):282-8 PMID: 11875500
  13. The cat and mouse games that genes, viruses, and cells play.
    Cell. 1997 Mar 7;88(5):573-5 PMID: 9054495
  14. The multiple roles of PTEN in tumor suppression.
    Cell. 2000 Feb 18;100(4):387-90 PMID: 10693755
  15. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.
    Mech Dev. 2001 Mar;101(1-2):61-9 PMID: 11231059
  16. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Mod Pathol. 2002 Jan;15(1):35-44 PMID: 11796839
  17. Intrinsic tumour suppression.
    Nature. 2004 Nov 18;432(7015):307-15 PMID: 15549092
  18. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.
    Cell. 2002 May 3;109(3):335-46 PMID: 12015983
  19. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
    Cancer Res. 1998 Jan 15;58(2):204-9 PMID: 9443392
  20. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Science. 2004 Feb 6;303(5659):844-8 PMID: 14704432
  21. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.
    J Urol. 1999 Jan;161(1):304-8 PMID: 10037428
  22. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.
    EMBO J. 2004 Jan 14;23(1):212-20 PMID: 14713953
  23. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.
    Nat Genet. 2001 Feb;27(2):222-4 PMID: 11175795
  24. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
    Nature. 2005 Jan 20;433(7023):278-85 PMID: 15662416
  25. PTEN/MMAC1 mutations in prostate cancer.
    Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S32 PMID: 12497140
  26. PTEN and p53: who will get the upper hand?
    Cancer Cell. 2003 Feb;3(2):97-9 PMID: 12620402
  27. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.
    Nat Cell Biol. 2001 Nov;3(11):973-82 PMID: 11715018
  28. Conditional mouse models of sporadic cancer.
    Nat Rev Cancer. 2002 Apr;2(4):251-65 PMID: 12001987
  29. Surfing the p53 network.
    Nature. 2000 Nov 16;408(6810):307-10 PMID: 11099028
  30. Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
    Oncogene. 1998 Apr 2;16(13):1743-8 PMID: 9582022
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
Published
2005-08-04
Pages
725-30
Language
English
Region
England
NLM ID
0410462
PMCID
PMC1939938
Subset
IM
Grants
NCI NIH HHS · P50 CA092629 · United States
NCI NIH HHS · R01 CA137050 · United States
NIMHD NIH HHS · R01 MD004038 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com